Q: What is Pembrolizumab used for?

Pembrolizumab is used to treat: melanoma non-small cell lung cancer head and neck squamous cell carcinoma and others

Q: What are the brand names for Pembrolizumab?

Pembrolizumab is sold under the brand name Keytruda .

Q: What are the active ingredients in Pembrolizumab?

The active ingredient in Pembrolizumab is pembrolizumab .

Q: What are the side effects of Pembrolizumab?

Common side effects of Pembrolizumab may include: Fatigue Pruritus Rash and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Pembrolizumab?

Pembrolizumab belongs to the PD-1 inhibitor drug class.

Q: What is the dosage of Pembrolizumab and how do I take it?

Administration Methods Pembrolizumab is given by a healthcare provider in a medical setting, such as a hospital or clinic. It is most commonly administered as an intravenous (IV) infusion , where the medication is dripped into a vein. In some cases, it may be given as a subcutaneous injection under the skin. Treatment Schedule The frequency of treatments depends on the specific condition being treated and how the patient responds to the medication. It is typically administered on a regular schedule every few weeks. The duration of the infusion process is determined by the healthcare provider and is performed under medical supervision. Missed Doses Because this medication is administered by a healthcare professional, it is important to keep all scheduled appointments. If an appointment is missed, patients should contact their doctor or clinic as soon as possible to reschedule the treatment and receive instructions on how to proceed.

Q: Is Pembrolizumab safe during pregnancy and breastfeeding?

Pregnancy Pembrolizumab can cause harm to a fetus when administered to a pregnant person. Before starting treatment, healthcare providers typically perform a pregnancy test to confirm that a patient is not pregnant. It is important to use effective birth control (contraception) during treatment and for at least 4 months after the final dose of the medication. If you become pregnant or think you might be pregnant while receiving this medication, notify your healthcare provider immediately to discuss the potential risks to the fetus. Breastfeeding It is not known if pembrolizumab passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least 4 months after the last dose. Patients should discuss the best way to feed their baby with their healthcare team during this time.

Q: What forms and strengths does Pembrolizumab come in?

Available Forms Pembrolizumab is provided in the following dosage forms: Intravenous Solution: A liquid solution supplied in single-dose vials for infusion into a vein. Subcutaneous Injection: A formulation combined with berahyaluronidase-alfa-pmph for injection under the skin. Administration This medication is administered by a doctor or nurse in a hospital or clinical facility. The intravenous infusion typically takes about 30 minutes. The specific dose and schedule are determined by a healthcare provider based on the patient's weight, the condition being treated, and how well the body responds to the medication.

Question 1

What is Pembrolizumab?

Accepted Answer

Pembrolizumab is a type of immunotherapy known as a monoclonal antibody. It is designed to help the immune system recognize and fight cancer cells within the body.

The medication works by blocking a protein called programmed death receptor-1 (PD-1), which normally prevents the immune system from attacking healthy cells. By inhibiting this protein, pembrolizumab allows immune cells to better detect and eliminate cancer cells.

Question 2

What is Pembrolizumab used for?

Accepted Answer

Pembrolizumab is used to treat:

melanoma
non-small cell lung cancer
head and neck squamous cell carcinoma
and others

Question 3

How does Pembrolizumab work?

Accepted Answer

The immune system uses specialized white blood cells called T cells to find and destroy threats, such as infections or abnormal cells. However, cancer cells can sometimes develop ways to "hide" from these T cells, allowing the cancer to grow and spread without being attacked.

Pembrolizumab is a monoclonal antibody that belongs to a class of drugs known as PD-1 inhibitors. PD-1 is a protein found on the surface of T cells that acts as a "checkpoint" or a brake. When PD-1 attaches to other proteins (called PD-L1 or PD-L2) found on some normal cells and cancer cells, it sends a signal to the T cell to stop attacking.

Many types of cancer cells produce these proteins to trick the immune system into leaving them alone. By binding to the PD-1 protein, pembrolizumab prevents it from connecting with the cancer cells' proteins. This action effectively "releases the brakes" on the immune system.

When the PD-1 pathway is blocked, T cells are better able to:

Recognize cancer cells as a threat.
Increase their activity and multiply.
Target and attack the tumor cells throughout the body.

Because this treatment works by enhancing the body's natural defenses rather than attacking cells directly like traditional chemotherapy, it is classified as an immunotherapy.

Question 4

What are the brand names for Pembrolizumab?

Accepted Answer

Pembrolizumab is sold under the brand name Keytruda.

Question 5

What are the active ingredients in Pembrolizumab?

Accepted Answer

The active ingredient in Pembrolizumab is pembrolizumab.

Question 6

What are the side effects of Pembrolizumab?

Accepted Answer

Common side effects of Pembrolizumab may include:

Fatigue
Pruritus
Rash
and others.

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Pembrolizumab?

Accepted Answer

Pembrolizumab belongs to the PD-1 inhibitor drug class.

Question 8

What is the dosage of Pembrolizumab and how do I take it?

Accepted Answer

Administration Methods

Pembrolizumab is given by a healthcare provider in a medical setting, such as a hospital or clinic. It is most commonly administered as an intravenous (IV) infusion, where the medication is dripped into a vein. In some cases, it may be given as a subcutaneous injection under the skin.

Treatment Schedule

The frequency of treatments depends on the specific condition being treated and how the patient responds to the medication. It is typically administered on a regular schedule every few weeks. The duration of the infusion process is determined by the healthcare provider and is performed under medical supervision.

Missed Doses

Because this medication is administered by a healthcare professional, it is important to keep all scheduled appointments. If an appointment is missed, patients should contact their doctor or clinic as soon as possible to reschedule the treatment and receive instructions on how to proceed.

Question 9

Is Pembrolizumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Pembrolizumab can cause harm to a fetus when administered to a pregnant person. Before starting treatment, healthcare providers typically perform a pregnancy test to confirm that a patient is not pregnant. It is important to use effective birth control (contraception) during treatment and for at least 4 months after the final dose of the medication.

If you become pregnant or think you might be pregnant while receiving this medication, notify your healthcare provider immediately to discuss the potential risks to the fetus.

Breastfeeding

It is not known if pembrolizumab passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least 4 months after the last dose. Patients should discuss the best way to feed their baby with their healthcare team during this time.

Question 10

What forms and strengths does Pembrolizumab come in?

Accepted Answer

Available Forms

Pembrolizumab is provided in the following dosage forms:

Intravenous Solution: A liquid solution supplied in single-dose vials for infusion into a vein.
Subcutaneous Injection: A formulation combined with berahyaluronidase-alfa-pmph for injection under the skin.

Administration

This medication is administered by a doctor or nurse in a hospital or clinical facility. The intravenous infusion typically takes about 30 minutes. The specific dose and schedule are determined by a healthcare provider based on the patient's weight, the condition being treated, and how well the body responds to the medication.

Question 11

What is the FDA approval status of Pembrolizumab?

Accepted Answer

FDA Approval Status

Pembrolizumab was first approved by the U.S. Food and Drug Administration (FDA) in 2014. It is classified as a programmed death receptor-1 (PD-1) blocking antibody. While originally approved as an intravenous (IV) medication, the FDA approved a subcutaneous version (pembrolizumab and hyaluronidase-alfa-pmph) in June 2024 for several adult indications.

Approved Indications

The FDA has approved pembrolizumab for numerous types of cancer, often based on specific genetic markers or previous treatment history. Key indications include:

Melanoma
Non-small cell lung cancer (NSCLC)
Head and neck squamous cell carcinoma
Classical Hodgkin lymphoma
Urothelial carcinoma
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers
Gastric or gastroesophageal junction adenocarcinoma
Cervical cancer
Triple-negative breast cancer

Recent regulatory actions include the June 2024 approval for use in combination with paclitaxel for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also approved for use with trastuzumab and chemotherapy for certain HER2-positive gastric cancers.

Safety and Monitoring

There are currently no FDA Boxed Warnings for pembrolizumab. However, the FDA monitors the drug for immune-related adverse reactions, which can affect various organs including the lungs, colon, liver, endocrine glands, and kidneys. Regulatory approval for certain uses may require specific diagnostic testing, such as PD-L1 expression levels or MSI-H/dMMR status, to determine if a patient is a candidate for treatment.

Question 12

What should I know about Pembrolizumab and cost?

Accepted Answer

Factors Affecting Cost

The total price of pembrolizumab treatment is influenced by several variables:

Dosage and Schedule: The specific dose and the frequency of administration (such as every three or six weeks) impact the overall cost.
Administration Method: Costs may vary between intravenous infusion and subcutaneous injection, as well as the fees associated with the healthcare facility providing the service.
Insurance Coverage: Most insurance providers, including Medicare and Medicaid, cover pembrolizumab for FDA-approved uses. However, out-of-pocket expenses like copays and deductibles can vary widely between plans.

Financial Assistance Programs

Because immunotherapy can be expensive, financial support options may be available to help patients manage costs:

Manufacturer Assistance: The drug manufacturer may offer patient assistance programs or co-pay coupons for those who meet specific eligibility criteria.
Charitable Foundations: Independent organizations sometimes provide grants to help cover the costs of cancer treatments for patients with financial need.

Patients should consult with their oncology team or hospital billing department to get an accurate estimate of costs and to explore available financial resources.

Pembrolizumab

📋Overview

How It Works

Uses

Brand Names

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Pembrolizumab

Hospitals.net Disclosure